ARWR
Arrowhead Pharmaceuticals, Inc. NASDAQ Listed Dec 16, 1993$77.87
After hrs
$72.70
+0.01%
Mkt Cap $10.9B
52w Low $12.44
97.6% of range
52w High $79.48
50d MA $64.54
200d MA $49.48
P/E (TTM)
-6132.0x
EV/EBITDA
28.8x
P/B
19.9x
Debt/Equity
0.8x
ROE
35.6%
P/FCF
29.4x
RSI (14)
—
ATR (14)
—
Beta
1.27
50d MA
$64.54
200d MA
$49.48
Avg Volume
2.7M
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
177 East Colorado Boulevard · Pasadena, CA 91105 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -1.09 | -0.93 | +15.1% | 77.95 | -1.9% | -6.7% | — | — | — | — | — |
| Feb 5, 2026 | AMC | 0.60 | 0.22 | -63.3% | 64.64 | +1.3% | -0.2% | -3.1% | -2.7% | -4.8% | -3.5% | — |
| Nov 25, 2025 | AMC | -0.11 | -0.18 | -61.3% | 46.79 | +1.3% | +23.3% | +12.6% | +20.2% | +23.9% | +39.1% | — |
| Aug 7, 2025 | AMC | -0.94 | -1.26 | -34.0% | 16.06 | -3.2% | +2.2% | +7.2% | +10.8% | +24.5% | +16.9% | — |
| May 12, 2025 | AMC | -0.06 | 2.75 | +4683.3% | 13.97 | +12.7% | +9.4% | +6.7% | +9.8% | +12.5% | +12.7% | — |
| Feb 10, 2025 | AMC | -0.42 | -1.39 | -231.0% | 19.92 | -8.5% | -5.2% | -6.8% | -4.1% | +0.2% | +2.6% | — |
| Nov 26, 2024 | AMC | -1.05 | -1.38 | -31.4% | 21.05 | +6.3% | +24.2% | +23.7% | +25.1% | +23.8% | +9.8% | — |
| Aug 8, 2024 | AMC | -0.58 | -1.38 | -137.9% | 25.85 | -3.3% | -9.4% | -11.3% | -11.6% | -12.2% | -12.3% | — |
| May 9, 2024 | AMC | -0.06 | -1.02 | -1600.0% | 24.72 | +3.1% | -10.7% | -10.8% | -7.3% | +1.3% | +1.1% | — |
| Feb 6, 2024 | AMC | -0.78 | -1.24 | -59.0% | 33.20 | -4.4% | -4.7% | -7.1% | -1.9% | -2.8% | -9.9% | — |
| Nov 29, 2023 | AMC | -0.70 | -1.03 | -47.1% | 28.98 | -3.0% | -26.8% | -20.0% | -14.0% | -19.2% | -17.9% | — |
| Aug 7, 2023 | AMC | -0.58 | -0.96 | -65.5% | 30.81 | -3.8% | -10.8% | -5.8% | -6.0% | -6.4% | -4.6% | — |
| May 2, 2023 | AMC | -0.64 | 0.45 | +170.3% | 35.38 | +6.0% | +13.6% | +13.2% | +17.0% | +14.3% | +14.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | JP Morgan | Initiates | Overweight | $88 | $73.48 | $74.56 | +1.5% | +1.8% | +4.0% | +2.0% | +7.7% | +6.1% |
| Apr 21 | Morgan Stanley | Upgrade | Equal-Weight → Overweight | $100 | $69.25 | $71.93 | +3.9% | +2.6% | +6.7% | +7.4% | +6.7% | +6.3% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.27 | $57.29 | +1.8% | +8.0% | +8.0% | +2.7% | +2.5% | +11.4% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.64 | $62.68 | +0.1% | +0.4% | -1.7% | -0.4% | +1.9% | +1.7% |
| Jan 22 | B. Riley Securities | Maintains | Buy → Buy | — | $67.60 | $68.95 | +2.0% | +2.9% | -0.8% | -1.2% | -1.0% | -3.0% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.28 | $65.76 | +0.7% | +3.6% | +6.6% | +2.7% | +2.4% | +2.5% |
| Jan 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $65.93 | $66.10 | +0.3% | -0.6% | -0.0% | +0.5% | -3.2% | -1.0% |
| Jan 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $70.81 | $66.13 | -6.6% | -7.2% | -8.2% | -8.8% | -6.9% | -7.4% |
| Jan 7 | Chardan Capital | Maintains | Buy → Buy | — | $70.81 | $66.13 | -6.6% | -7.2% | -8.2% | -8.8% | -6.9% | -7.4% |
| Jan 7 | Goldman Sachs | Maintains | Neutral → Neutral | — | $70.81 | $66.13 | -6.6% | -7.2% | -8.2% | -8.8% | -6.9% | -7.4% |
| Dec 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $64.66 | $65.90 | +1.9% | +0.2% | +2.8% | +5.4% | +6.7% | +8.0% |
| Dec 11 | RBC Capital | Maintains | Outperform → Outperform | — | $68.87 | $68.86 | -0.0% | +2.8% | +1.8% | -0.6% | -6.1% | -5.9% |
| Dec 9 | BofA Securities | Maintains | Buy → Buy | — | $68.60 | $65.69 | -4.2% | +0.3% | +0.4% | +3.2% | +2.2% | -0.2% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.25 | $55.91 | -0.6% | +3.0% | +15.7% | +15.0% | +9.2% | +22.0% |
| Dec 1 | Chardan Capital | Maintains | Buy → Buy | — | $52.70 | $52.37 | -0.6% | +6.7% | +10.0% | +23.5% | +22.7% | +16.6% |
| Dec 1 | BofA Securities | Maintains | Buy → Buy | — | $52.70 | $52.37 | -0.6% | +6.7% | +10.0% | +23.5% | +22.7% | +16.6% |
| Nov 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $46.79 | $47.39 | +1.3% | +23.3% | +12.6% | +20.2% | +23.9% | +39.1% |
| Nov 20 | Goldman Sachs | Maintains | Neutral → Neutral | — | $38.97 | $39.51 | +1.4% | -2.3% | +3.8% | +13.6% | +20.1% | +48.1% |
| Nov 19 | Chardan Capital | Maintains | Buy → Buy | — | $40.47 | $41.06 | +1.5% | -3.7% | -5.9% | -0.0% | +9.4% | +15.6% |
| Nov 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $40.47 | $41.06 | +1.5% | -3.7% | -5.9% | -0.0% | +9.4% | +15.6% |
| Nov 19 | RBC Capital | Maintains | Outperform → Outperform | — | $40.47 | $41.06 | +1.5% | -3.7% | -5.9% | -0.0% | +9.4% | +15.6% |
| Nov 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $41.50 | $41.96 | +1.1% | -0.2% | -0.9% | -0.6% | -3.3% | -2.5% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.54 | $36.90 | +1.0% | +1.1% | -1.3% | -3.1% | -0.8% | -1.6% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.03 | $22.73 | +3.2% | +16.6% | +26.2% | +27.1% | +32.0% | +23.3% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $16.42 | $16.30 | -0.7% | +4.8% | +8.4% | +21.7% | +14.4% | +24.9% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $16.06 | $15.55 | -3.2% | +2.2% | +7.2% | +10.8% | +24.5% | +16.9% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.74 | $15.86 | +0.8% | +3.5% | -2.7% | -2.2% | -3.9% | -2.4% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $13.97 | $15.75 | +12.7% | +9.4% | +6.7% | +9.8% | +12.5% | +12.7% |
| May 13 | Citigroup | Maintains | Neutral → Neutral | — | $13.97 | $15.75 | +12.7% | +9.4% | +6.7% | +9.8% | +12.5% | +12.7% |
| Feb 14 | B. Riley Securities | Maintains | Buy → Buy | — | $19.11 | $19.27 | +0.8% | +4.4% | +7.0% | +10.3% | +9.7% | +4.1% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.89 | $18.35 | -2.9% | -1.7% | +1.2% | +5.6% | +8.2% | +11.6% |
| Feb 11 | Chardan Capital | Maintains | Buy → Buy | — | $19.92 | $18.23 | -8.5% | -5.2% | -6.8% | -4.1% | +0.2% | +2.6% |
| Feb 11 | RBC Capital | Maintains | Outperform → Outperform | — | $19.92 | $18.23 | -8.5% | -5.2% | -6.8% | -4.1% | +0.2% | +2.6% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.71 | $20.05 | +1.7% | +9.2% | +5.3% | +2.7% | +1.6% | +1.2% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.76 | $19.71 | -0.3% | -0.3% | +9.0% | +5.1% | +2.5% | +1.4% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.50 | $19.38 | -0.6% | -0.3% | +1.3% | +0.7% | +0.2% | -2.8% |
| Dec 12 | Chardan Capital | Maintains | Buy → Buy | — | $22.73 | $22.65 | -0.4% | -2.6% | -3.9% | -1.6% | -2.0% | -10.4% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.34 | $26.27 | -0.3% | -1.0% | -12.3% | -15.3% | -10.4% | -11.7% |
| Nov 29 | Bernstein | Maintains | Market Perform → Market Perform | — | $26.15 | $26.15 | +0.0% | -0.5% | +0.7% | -0.3% | -11.6% | -14.7% |
| Nov 27 | Chardan Capital | Maintains | Buy → Buy | — | $21.05 | $22.37 | +6.3% | +24.2% | +23.7% | +25.1% | +23.8% | +9.8% |
| Nov 27 | Citigroup | Maintains | Neutral → Neutral | — | $21.05 | $22.37 | +6.3% | +24.2% | +23.7% | +25.1% | +23.8% | +9.8% |
| Nov 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.05 | $22.37 | +6.3% | +24.2% | +23.7% | +25.1% | +23.8% | +9.8% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.60 | $18.56 | -0.2% | +0.6% | -1.7% | -0.3% | +1.0% | +13.2% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.70 | $17.64 | -0.3% | +4.2% | +9.4% | +12.3% | +19.2% | +17.7% |
| Oct 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $18.13 | $18.13 | +0.0% | -0.6% | -1.6% | -2.4% | +1.7% | +6.8% |
| Sep 26 | RBC Capital | Maintains | Outperform → Outperform | — | $19.42 | $19.69 | +1.4% | +1.0% | +1.3% | -0.3% | -1.2% | -1.0% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.98 | $24.20 | +0.9% | -3.0% | -7.3% | -9.3% | -10.5% | -12.7% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.83 | $24.02 | +0.8% | -3.9% | +0.6% | -2.4% | -6.8% | -8.7% |
| Aug 12 | B. Riley Securities | Maintains | Buy → Buy | — | $23.41 | $23.43 | +0.1% | -2.0% | -2.3% | -3.0% | -3.2% | -3.0% |
| Jul 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.75 | $28.60 | -0.5% | +0.1% | +0.6% | +0.7% | -1.9% | -0.3% |
No insider trades available.
8-K
Madrigal Pharmaceuticals, Inc. -- 8-K Filing
Madrigal Pharmaceuticals reported strong Q1 2026 results for its MASH-focused pipeline, with CEO Bill Sibold signaling positive momentum heading into the year.
May 6
8-K
Unknown — 8-K Filing
This is a routine SEC filing document cover page with standard corporate identification information; it contains no material business updates that would impact ARWR's stock valuation or investor decisions.
Mar 20
8-K
Arrowhead Research Corporation -- 8-K Filing
Arrowhead Pharmaceuticals reported Q1 fiscal 2026 results and is hosting a conference call today, providing investors with updates on financial performance and pipeline progress.
Feb 5
Data updated apr 24, 2026 7:06pm
· Source: massive.com